Literature DB >> 15894321

Fibrates and coronary risk reduction.

George Steiner1.   

Abstract

Many medications are currently available to correct lipoprotein abnormalities when lifestyle measures alone are not sufficient. No single agent or class of agents is able to correct all of the lipoprotein abnormalities. This paper reviews the role of one class, the fibrates, in the management of lipid disorders and summarizes the clinical trial information relating to their impact on coronary artery disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15894321     DOI： 10.1016/j.atherosclerosis.2005.04.002

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


  3 in total

1.  A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.

Authors:  Marguerite R Irvin; Daniel M Rotroff; Stella Aslibekyan; Degui Zhi; Bertha Hidalgo; Alison Motsinger-Reif; Skylar Marvel; Vinodh Srinivasasainagendra; Steven A Claas; John B Buse; Robert J Straka; Jose M Ordovas; Ingrid B Borecki; Xiuqing Guo; Ida Y D Chen; Jerome I Rotter; Michael J Wagner; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2016-07       Impact factor: 2.089

2.  A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Authors:  Jeffrey E Ming; Ruth E Abrams; Derek W Bartlett; Mengdi Tao; Tu Nguyen; Howard Surks; Katherine Kudrycki; Ananth Kadambi; Christina M Friedrich; Nassim Djebli; Britta Goebel; Alex Koszycki; Meera Varshnaya; Joseph Elassal; Poulabi Banerjee; William J Sasiela; Michael J Reed; Jeffrey S Barrett; Karim Azer
Journal:  Gene Regul Syst Bio       Date:  2017-06-22

Review 3.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.